Patents Examined by Taeyoon Kim
-
Patent number: 9868935Abstract: The present disclosure describes a method and composition for enhancing the survival of hematopoietic stem cells, preferably CD34+ derived from human umbilical cord or peripheral blood, in hypoxic and serum-deprived conditions by cultivating the cells in medium containing lysophosphatidic acid, preferably further comprising a gel, namely a biomimetic gel. The method and composition may be used in medicine or cosmetic application, in particular, in treatment of cardiac tissue and/or cardiac diseases, and/or in the treatment of wound healing namely diabetic wound healing.Type: GrantFiled: April 24, 2013Date of Patent: January 16, 2018Assignee: CRIOESTAMINAL, SAÚDE E TECNOLOGIA, SA.Inventors: Lino Da Silva Ferreira, Isabel Maria Fidalgo Dos Santos Silva Carvalho
-
Patent number: 9856449Abstract: The invention provides systems and methods for generating organic compounds using carbon dioxide as a source of carbon and electrical current as an energy source. In one embodiment, a reaction cell is provided having a cathode electrode and an anode electrode that are connected to a source of electrical power, and which are separated by a permeable membrane. A biological film is provided on the cathode. The biological film comprises a bacterium that can accept electrons and that can convert carbon dioxide to a carbon-bearing compound and water in a cathode half-reaction. At the anode, water is decomposed to free molecular oxygen and solvated protons in an anode half-reaction. The half-reactions are driven by the application of electrical current from an external source. Compounds that have been produced include acetate, butanol, 2-oxobutyrate, propanol, ethanol, and formate.Type: GrantFiled: September 21, 2015Date of Patent: January 2, 2018Assignee: UNIVERSITY OF MASSACHUSETTSInventors: Derek R. Lovley, Kelly P. Nevin
-
Patent number: 9855300Abstract: The invention relates to a composition and method used for injuries treatment with a surprisingly therapeutic effect. This composition comprises a population of cells derived from human umbilical cord blood which expresses one of the following markers: CD34, CD45, and CD31; a population of CD34+ derived endothelial cells; and a biomimetic gel, preferably fibrin. The method for obtaining the composition comprises the derivation of a population of endothelial cells from CD34+ cells and then a co-culture of a CD34+ cells with CD34+-derived endothelial cells within a biomimetic gel.Type: GrantFiled: November 28, 2011Date of Patent: January 2, 2018Assignee: CRIOESTAMINAL, SAÚDE E TECNOLOGIA, SA.Inventors: Lino Da Silva Ferreira, Dora Cristina Dos Santos Pedroso
-
Patent number: 9855288Abstract: The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement.Type: GrantFiled: July 9, 2015Date of Patent: January 2, 2018Assignee: MANNATECH, INCORPORATEDInventor: Robert A. Sinnott
-
Patent number: 9849157Abstract: A composition for use in cardiovascular therapy includes transfer factor. The transfer factor may be nonmammalian transfer factor, such as that derived from eggs, or mammalian transfer factor, such as that derived from colostrum. The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element; a cholesterol reducing element; a fat oxidation prevention element, and an antioxidant. Treatment methods include enlisting the immune system of a subject receiving therapy to attack pathogens that cause inflammation of blood vessels or to otherwise reduce inflammation of blood vessels.Type: GrantFiled: October 18, 2010Date of Patent: December 26, 2017Assignee: 4LIFE PATENTS, LLCInventor: William J. Hennen
-
Patent number: 9851304Abstract: The invention relates to a method for monitoring a cryopreserved biological sample (1), comprising the steps of providing the biological sample (1) in a cryopreserved state, measuring at least one Raman spectroscopic sample characteristic by means of a Raman spectroscopic measuring apparatus (10, 20), comparing the at least one sample characteristic with a reference characteristic by means of an evaluating apparatus (30), and providing a state characteristic that depends on the result of the comparison and that is characteristic of a storage state of the biological sample (1). The invention further relates to a monitoring device for cryopreserved samples, in particular for performing said method.Type: GrantFiled: October 26, 2011Date of Patent: December 26, 2017Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.Inventors: Guenter R. Fuhr, Heiko Zimmermann, Frank Stracke, Daniel Doerr
-
Patent number: 9844571Abstract: The present invention relates to a method of treating a subject having a disorder comprising administering to the subject an effective amount of a stem/progenitor cell isolated from the amniotic membrane of the umbilical cord or an effective amount of a cellular extract thereof.Type: GrantFiled: November 27, 2015Date of Patent: December 19, 2017Assignee: CELLRESEARCH CORPORATION PTE LTDInventors: Toan-Thang Phan, Ivor Jiun Lim
-
Patent number: 9845483Abstract: The invention relates to an alcoholic fermentation process in the presence of one or more high alcohol tolerant yeast and one or more maltotriose positive yeast. The process of the present invention can be a fermentation process for the production of ethanol, for the production of beer, for the production of wine and the like. in a preferred embodiment, the present invention relates to a process for the production of ethanol in the presence of distiller's yeast and baker's yeast.Type: GrantFiled: May 31, 2013Date of Patent: December 19, 2017Assignee: CARGILL, INCORPORATEDInventors: Jean-Claude Marie Pierre De Troostembergh, Bernhard Horbach, Michael Josef Christian Kruse, Nicolas Andre Albert Meurens
-
Patent number: 9839679Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.Type: GrantFiled: February 26, 2014Date of Patent: December 12, 2017Assignee: Acorda Therapeutics, Inc.Inventors: Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
-
Patent number: 9808485Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: January 6, 2012Date of Patent: November 7, 2017Assignees: Athersys, Inc., Oregon Health And Science UniversityInventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Patent number: 9810618Abstract: Provided herein are systems and methods for analyzing blood samples, and more specifically for performing a basophil analysis. In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; and then (b) using measurements of light scatter and fluorescence emission to distinguish basophils from other WBC sub-populations. In one embodiment, the systems and methods include performing a basophil cluster analysis of the blood sample, based on the combination of light scatter and fluorescence measurements.Type: GrantFiled: July 24, 2015Date of Patent: November 7, 2017Assignee: Abbott LaboratoriesInventors: Jiong Wu, Michael R. Buhl, Giacomo Vacca
-
Patent number: 9809477Abstract: The present invention relates to methods for preventing and/or reducing biofilm formation and/or planktonic proliferation with one or more selected bacteria strains or bacterial blends.Type: GrantFiled: April 27, 2015Date of Patent: November 7, 2017Assignee: NOVOZYMES BIOLOGICALS, INC.Inventors: Sarah McHatton, Irene Michelle Williams, David Drahos
-
Patent number: 9803173Abstract: The subject matter of the present invention is a device for guiding cell migration comprising a substrate having a textured surface intended to be brought into contact with cells, said textured surface having an anisotropic three-dimensional structure consisting of a network of projections inclined relative to the normal to the plane formed by said textured structure, in the direction imparted by said anisotropic structure. The invention also concerns, according to another aspect, a method for guiding cell migration including the bringing into contact of cells with a substrate having a textured surface and an anisotropic three-dimensional structure, said structure consisting of projections inclined as previously described. The device or method according to the invention can in particular be applied in the fields of dermatology, implantology and tissue engineering.Type: GrantFiled: September 17, 2012Date of Patent: October 31, 2017Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, SOCIETE DE DEVELOPPEMENT ET DE RECHERCHE INDUSTRIELLEInventors: Mael Le Berre, Matthieu Piel, Yong Chen, Yanjun Liu
-
Patent number: 9797824Abstract: A method whereby one or more fluorescent dyes are used to bind and stain nucleic acids in certain blood cells, such as, for example, white blood cells, nucleated red blood cells, and reticulocytes, and to induce fluorescent emissions upon excitation of photons from a given source of light, such as, for example, a laser, at an appropriate wavelength. More particularly, this invention provides a method whereby a fluorescent trigger is used in a data collection step for collecting events that emit strong fluorescence, in order to separate white blood cells and nucleated red blood cells from red blood cells and platelets without the need for using a lysing agent.Type: GrantFiled: July 24, 2015Date of Patent: October 24, 2017Assignee: Abbott LaboratoriesInventors: Jiong Wu, Giacomo Vacca
-
Patent number: 9790464Abstract: The present invention relates to a cell culture medium for culturing human cells comprising an anti-coagulated total blood material wherein the hemoglobin level is from about 8 to about 16 g/dl. More particularly, the invention provides a cell culture medium in which cells present in the blood are disrupted and the insoluble remnants of the lysated cells are removed. Further, the invention provides a method for the preparation of a cell culture medium for culturing human cells, according to the invention.Type: GrantFiled: September 24, 2010Date of Patent: October 17, 2017Assignee: BioMarker Kft.Inventors: Henriette Skribek, László Székely
-
Patent number: 9778162Abstract: Systems and methods for analyzing blood samples, and more specifically for performing a white blood cell (WBC) differential analysis. The systems and methods screen WBCs by means of fluorescence staining and a fluorescence triggering strategy. As such, interference from unlyzed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder WBC reagent(s), suitable for assays of samples containing fragile WBCs. In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye, which corresponds in emission spectrum to an excitation source of a hematology instrument; (b) using a fluorescence trigger to screen the blood sample for WBCs; and (c) using measurements of (1) axial light loss, (2) intermediate angle scatter, (3) 90° polarized side scatter, (4) 90° depolarized side scatter, and (5) fluorescence emission to perform a differentiation analysis.Type: GrantFiled: July 24, 2015Date of Patent: October 3, 2017Assignee: Abbott LaboratoriesInventors: Jiong Wu, Giacomo Vacca
-
Patent number: 9778161Abstract: A set of 10 or more standards containing a defined number of particles from 1000 to 1,000,000 wherein the defined number of particles is within a degree of error of 10% or less between each standard of the set.Type: GrantFiled: January 31, 2007Date of Patent: October 3, 2017Assignee: BFT PTY LTDInventors: Graham Vesey, Nick Herman, Charlotte Morgan
-
Patent number: 9778163Abstract: Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.Type: GrantFiled: July 24, 2015Date of Patent: October 3, 2017Assignee: Abbott LaboratoriesInventors: Jiong Wu, Marilou Coleman, Emily H. Lin, Michael R. Buhl, Giacomo Vacca
-
Patent number: 9770471Abstract: The present invention provides methods of transdifferentiation of somatic cells, for example, directly converting a somatic cell of a first cell type, e.g., a fibroblast into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for converting a somatic cell, e.g., a fibroblast into a motor neuron, e.g., an induced motor neuron (iMN) with characteristics of a typical motor neuron. The present invention also relates to an isolated population comprising induced motor neurons (iMNs), compositions and their use in the treatment of motor neuron diseases such as ALS and SMA. In particular, the present invention relates to direct conversion of a somatic cell to an induced motor neuron (iMN) having motor neuron characteristics by increasing the protein expression of at least three motor-neuron inducing (MN-inducing) factors selected from Lhx3, Ascl1, Brn2, Myt1l, Isl1, Hb9, Ngn2 or NeuroD1 in a somatic cell, e.g.Type: GrantFiled: August 17, 2012Date of Patent: September 26, 2017Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Kevin Carl Eggan, Clifford J. Woolf, Brian J. Wainger, Justin K. Ichida, Esther Yesde Son
-
Patent number: 9770494Abstract: A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.Type: GrantFiled: June 27, 2014Date of Patent: September 26, 2017Assignee: ThromboGenics NVInventors: Steve Pakola, Marc De Smet